Aktienanalyse zu EyePoint Inc (EYPT)EYPTEyePoint Inc

EyePoint, Inc., formerly EyePoint Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The Company’s lead product candidate, DURAVYU, is an investigational-sustained delivery treatment for serious retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, with bioerodible Durasert E technology. Vorolanib features a novel multi-mechanism of action as it targets both vascular endothelial growth factor (VEGF)-mediated vascular permeability and IL-6 mediated inflammation through inhibition of all VEGF receptors and pro-inflammatory IL-6/JAK1 signaling. DURAVYU is in Phase III pivotal trials for wet age-related macular degeneration. DURAVYU is also being advanced for the treatment of diabetic macular edema (DME) with the first patient dosing in Phase III trials. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

EyePoint Pharmaceuticals is not a good buy right now due to its recent significant stock decline and ongoing financial struggles. The current price is $4.48, and the stock has dropped 74.37% year-to-date. Additionally, the RSI is at a very low 22.09, indicating oversold conditions, but this is not a strong enough signal to outweigh the risks. The main risk is the company's ongoing net losses, which reached -$94,470,000 in Q2 2026, and the failure of its key clinical trial, which has led to a loss of investor confidence and a downgrade in ratings.